FKBP1A
Peptidyl-prolyl cis-trans isomerase FKBP1A
Protein Summary
Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruits SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. The protein encoded by this gene is a member of the immunophilin protein family, which play a role in immunoregulation and basic cellular processes involving protein folding and trafficking. The protein is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 and rapamycin. It interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. It also interacts with multiple intracellular calcium release channels, and coordinates multi-protein complex formati ...more
- ENST00000381719
- ENSP00000371138
- ENSG00000088832
- ENST00000400137
- ENSP00000383003
- FKBP1
- FKBP12
- FKBP1
- PKC12
- PKCI2
- FKBP12
- PPIASE
- FKBP-12
- FKBP-1A
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 1 | ||
disease perturbation | 1 | ||
transcription factor perturbation | 1 | ||
kinase perturbation | 0.98 | ||
molecular function | 0.97 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 875.33 (req: < 5)
Gene RIFs: 53 (req: <= 3)
Antibodies: 377 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 875.33 (req: >= 5)
Gene RIFs: 53 (req: > 3)
Antibodies: 377 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 31
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 435
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 5